Trials / Not Yet Recruiting
Not Yet RecruitingNCT07174414
Cilostazol for Prevention of Recurrent Stroke Trial
- Status
- Not Yet Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 2,000 (estimated)
- Sponsor
- Stanford University · Academic / Other
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical trial is to learn whether adding cilostazol to aspirin or clopidogrel prevents stroke and heart attack in people who have had a stroke or mini-stroke.
Conditions
- Stroke Recurrence
- Myocardial Infarction
- Vascular Death
- Ischemic Stroke
- TIA (Transient Ischemic Attack)
- Stroke (CVA) or Transient Ischemic Attack
- Recurrent Stroke
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cilostazol 100 mg | Cilostazol 100 mg tablet taken orally twice daily following an initial 2-week period during which cilostazol is dosed at 100 mg tablet taken orally once daily to maximize tolerability. |
| DRUG | Placebo | Placebo 100 mg tablet twice taken orally daily following an initial 2-week period during which placebo is dosed at 100 mg taken orally once daily to maximize tolerability. |
Timeline
- Start date
- 2026-08-01
- Primary completion
- 2031-07-01
- Completion
- 2031-07-01
- First posted
- 2025-09-16
- Last updated
- 2025-09-16
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07174414. Inclusion in this directory is not an endorsement.